Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- Nichi-Iko to Shift Back Priority to Its Own Generics from Transferred Long-Listed Products
February 13, 2012
- Takeda Sets Up Development Center at China Subsidiary to Boost Development in Asia
February 10, 2012
- Eisai to Transfer Shares and Equity of its Pharmaceutical Machinery Business Subsidiaries
February 10, 2012
- Nomura Report Recommends Otsuka HD, DSP, Eisai Shares
February 10, 2012
- Mr Takeuchi of Astellas Stresses Importance of IP Strategies in Tie-ups with Bioventures
February 10, 2012
- Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020
February 9, 2012
- Sales of Ethical Drugs Up 5.3% in December: Crecon Report
February 9, 2012
- Meiji Seika Pharma Begins PII Trial of Schizophrenia Drug Ziprasidone in Japan
February 9, 2012
- Santen Pharmaceutical Apr-Dec Sales Up 5.3% on Steady Growth in Japan and Abroad
February 8, 2012
- Novartis President Mitani Says Diovan Patent Expiry an “Urgent Issue”
February 8, 2012
- Novartis Domestic Sales Up 6% Despite Drop in Diovan
February 8, 2012
- All-Case PMS for Chugai’s Tarceva for NSCLC Lifted
February 8, 2012
- Janssen Files NDA for Anti-HIV Agent Edurant in Japan
February 8, 2012
- JCR Hopes to Build Delivery Network, Boost Product Promotion in Collaboration with Medipal: Chairman Ashida
February 7, 2012
- DSP President Tada Says Steady Shift to Latuda Seen in US
February 7, 2012
- JCR to Push Joint Development with GSK, Including New Biopharmaceuticals
February 7, 2012
- Apr-Dec Sales Rise 7.4% due to Vidaza: Nippon Shinyaku
February 7, 2012
- Apr-Dec Sales Up 1.9% Driven by Artz: Kaken
February 7, 2012
- Astellas to Establish New Global Human Resources Committee on April 1
February 7, 2012
- Takeda Announces US Launch of Combination Hypertension Treatment Edarbyclor
February 7, 2012
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…